Research Article Characterization of Schizophrenia Adverse Drug Interactions through a Network Approach and Drug Classification

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Antipsychotic drugs aremedications commonly for schizophrenia (SCZ) treatment, which include two groups: typical and atypical. SCZpatients havemultiple comorbidities, and the coadministration of drugs is quite common.Thismay result in adverse drug-drug interactions, which are events that occur when the effect of a drug is altered by the coadministration of another drug. Therefore, it is important to provide a comprehensive view of these interactions for further coadministration improvement. Here, we extracted SCZ drugs and their adverse drug interactions from the DrugBank and compiled a SCZ-specific adverse drug interaction network. This network included 28 SCZ drugs, 241 non-SCZs, and 991 interactions. By integrating the Anatomical Therapeutic Chemical (ATC) classification with the network analysis, we characterized those interactions. Our results indicated that SCZ drugs tended to have more adverse drug interactions than other drugs. Furthermore, SCZ typical drugs had significant interactions with drugs o